Level of instruction: Beginning
Intended audience: Medical laboratory scientists, medical technologists, and technicians, This course is also appropriate for clinical laboratory science students and pathology residents.
Author information: David J. Moffa, PhD, BCLD has over 30 years of experience in the healthcare industry as an executive manager, clinical laboratory director, and medical laboratory scientist. He is currently a technical consultant for Kentmere Healthcare, Wilmington, DE, and until his retirement, was the Regional Director for LabCorp, Inc. He holds a PhD in medical biochemistry from the School of Medicine, West Virginia University.
Reviewer information: Judi Bennett, MT, BSM is currently a Program Director for MediaLab, Inc. in Lawrenceville, Georgia. She has over 30 years of medical laboratory experience in an acute care hospital setting as a laboratory manager, senior clinical applications specialist, point-of-care coordinator, microbiology supervisor, and generalist technologist. Judi has experience speaking at various professional conferences and is the author of numerous peer-reviewed publications.
Course description: Liquid biopsy is a rapidly advancing field with a growing number of companies involved in the development of these assays for the diagnosis and stratification of cancer patients. Because liquid biopsy can potentially provide a comprehensive, real-time assessment of the whole tumor burden for an individual patient, many experts believe it has the potential to replace the standard tissue biopsy. This course will discuss the primary molecular biomarkers detected in blood via liquid biopsy assay, including circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and exosomes.